Last reviewed · How we verify

AL101 — Competitive Intelligence Brief

AL101 (AL101) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: PI3K/AKT/mTOR inhibitor. Area: Oncology.

phase 2 PI3K/AKT/mTOR inhibitor PI3K/AKT/mTOR pathway Oncology Small molecule Live · refreshed every 30 min

Target snapshot

AL101 (AL101) — Ayala Pharmaceuticals, Inc,. AL101 is an inhibitor of the PI3K/AKT/mTOR pathway.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
AL101 TARGET AL101 Ayala Pharmaceuticals, Inc, phase 2 PI3K/AKT/mTOR inhibitor PI3K/AKT/mTOR pathway

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (PI3K/AKT/mTOR inhibitor class)

  1. Ayala Pharmaceuticals, Inc, · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). AL101 — Competitive Intelligence Brief. https://druglandscape.com/ci/al101. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: